Interim analysis of a phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic al amyloidosis (AL)

✍ Scribed by A.D. Cohen; P. Zhou; L. Reich; S. Fircanis; L. Drake; C. Hedvat; J. Teruya-Feldstein; D.A. Filippa; M. Fleisher; R.L. Comenzo

• Book ID: 116277977
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 63 KB
• Volume: 11
• Category: Article
• ISSN: 1083-8791
• DOI: 10.1016/j.bbmt.2004.12.020